Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search for Articles Submit an Article for Review

Keyword: brca

81 through 90 of 112

Relevance: Medium

Strength of Science: Medium-Low

View Related Clinical Trials

Study : Angelina Jolie spoke out on BRCA testing: Did genetic testing increase?

Most relevant for: People interested in genetic testing for an inherited mutation

Angelina Jolie published an editorial in the New York Times in 2013 about her choice to have a double mastectomy after finding out she was positive for a BRCA1 mutation. Researchers from a recent study claim that her celebrity endorsement of BRCA testing may have missed its target audience (previvors), due to the increase in BRCA testing following publication of the editorial but a decrease in the number of mastectomies performed. However, the study failed to take into account that many women without breast cancer do not pursue mastectomy in the months following genetic testing. (1/4/17)

Read More

Relevance: Medium

Strength of Science: Medium-High

View Related Clinical Trials

Study : Removing ovaries before age 50 may increase the risk of chronic conditions for some women

Most relevant for: Women under 50 years of age who have had or are considering removing their ovaries

Removal of ovaries and fallopian tubes prevents ovarian cancer, but it may come with other health risks. Experts recommend removal of ovaries and fallopian tubes in women at high risk for ovarian cancer due to inherited mutations in BRCA or other genes linked to ovarian cancer risk. For these high-risk women the benefit of ovarian cancer prevention outweighs the risk of long-term complications. Based on a recent study, some researchers feel that for women who are not at increased risk for cancer, the risk for some chronic conditions is too high to consider removal of both ovaries. (11/1/16)

Read More

Relevance: Medium

Strength of Science: Medium

View Related Clinical Trials

Study : Breast cancer screening should be tailored to a woman’s risk factors and breast density

Most relevant for: Women who are at high risk for breast cancer due to family history, dense breasts, LCIS, or multiple biopsies

The United States Preventative Services Task Force (USPSTF) recommends a screening mammogram every other year for women ages 50-74 who are at average risk for breast cancer. But do all patients in this category benefit from this screening regimen? 10/18/16

Read More

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Study : Rare mutations in PALB2, CHEK2, and ATM: how much do they increase cancer risk?

Most relevant for: People who tested positive for one of the rare variants in CHEK2, ATM or PALB2 that are covered in this study

As multi-gene panel tests become more common, people are discovering they have mutations in genes that are not understood as well as BRCA. This can make it difficult to give patients accurate assessments of their cancer risk. For example, mutations in PALB2, CHEK2, and ATM are rare, but some specific changes in these genes are even less common. The goal of this international collaboration was to better understand the cancer risks of some very rare PALB2, CHEK2, and ATM mutations. The findings are relevant only to the specific mutations covered in this paper and do not apply to all people with mutations in PALB2, CHEK2, or ATM. (9/27/16)

Read More

Relevance: Medium

Strength of Science: Medium-High

View Related Clinical Trials

Study : Does IVF increase a woman’s risk for breast cancer?

Most relevant for: Woman at average risk for breast cancer who have or are considering undergoing In Vitro Fertilization

In vitro fertilization (IVF) wasn't commonly used until the 1980s, so its long-term effects are mostly unknown. A new study suggests that the treatment does not increase a woman's risk for developing breast cancer. (8/23/16)

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Extending aromatase inhibitor duration to 10 years lowers recurrence for ER/PR+ breast cancer patients

Most relevant for:

Hormonal therapy reduces the risk of recurrence for women with early-stage breast cancer that is ER-and/or PR-positive. Standard therapy lasts 5 years. A new study looks at whether extending one type of hormonal therapy, known as aromatase inhibitor therapy, to 10 years lowers recurrence rates even more for these women. (7/26/16)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Racial disparities in BRCA testing: Why?

Most relevant for: African American women who have been diagnosed with breast cancer

Black women receive BRCA testing less frequently than white women. Why is that? Researchers thought the reason might be that black and white women see different health care providers. However, new research suggests that disparities in physician recommendations for testing are the cause: black women with breast cancer were less likely to receive physician recommendations for BRCA testing than white women with breast cancer. There is a need to ensure equity in physician testing recommendations for black women. (7/21/16)

Read More

Relevance: Medium

Strength of Science: Medium

Research Timeline: Human Research

View Related Clinical Trials

Study : Early research on a drug to prevent breast cancer

Most relevant for: Women with a BRCA1 mutation

Many researchers are interested in non-surgical options to reduce the higher-than-average risk of developing breast cancer in BRCA mutation carriers. This research study identified a type of drug, called a “RANK ligand inhibitor,” that may prevent breast cancer. Among mice that were genetically engineered to have no BRCA1 genes, those that were given the drug developed tumors less frequently than those that did not. While this is an exciting early study for BRCA mutation carriers, more work and human clinical trials need to be done before this can be used as a prevention therapy in humans. (7/12/16)

Update added 11/24/19: The RANK ligand inhibitor, denosumab is currently being studied as a possible breast and ovarian cancer preventive agent in human clinical trials.

Read More

Relevance: Medium

Strength of Science: Medium

Research Timeline: Human Research

View Related Clinical Trials

Study : Breast cancer risk model updated for average risk women with genetic, lifestyle and environmental information

Most relevant for: Women at average risk for breast cancer

A number of factors are known to increase breast cancer risk, but some of these factors have not been included in models to predict breast cancer risk. This study looks at an updated model that includes some of these factors, such as genetics, smoking, and drinking. The goal of the model is to give women a more individualized breast cancer risk assessment. (6/29/16)

Read More

Relevance: Medium-High

Strength of Science: Medium

View Related Clinical Trials

Study : Does light alcohol consumption affect your breast cancer risk?

Most relevant for: Women who drink alcohol and are concerned about their breast cancer risk.

Alcohol is known to increase breast cancer risk, but does that include light consumption? This study indicates that some breast cancer occurrences and mortality is due to light alcohol consumption. (06/21/16)

Read More